Loading...
Continuous inhibition of epidermal growth factor receptor phosphorylation by erlotinib enhances antitumor activity of chemotherapy in erlotinib-resistant tumor xenografts
Erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been shown to have benefits for non-small cell lung cancer and pancreatic cancer patients; however, almost all patients develop progressive disease during the therapy. On the other hand, it has been reported that a tumor c...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
D.A. Spandidos
2011
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3583539/ https://ncbi.nlm.nih.gov/pubmed/22209766 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/or.2011.1614 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|